| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -51,924 | -36,478 |
| Depreciation, amortization, and impairment | 418 | 279 |
| Gain on contract termination | 0 | 0 |
| Share-based compensation | 6,248 | 3,471 |
| Amortization of debt issuance costs and discounts | 8,246 | 5,498 |
| Other, net | 0 | 11 |
| Trade and other receivables, net | 4,413 | 4,476 |
| Inventories | 1,840 | 2,081 |
| Prepaid expenses and other assets | -1,383 | -3,104 |
| Accounts payable | 276 | 1,582 |
| Accrued expenses and other liabilities | -2,058 | -2,176 |
| Deferred revenue | -299 | -26 |
| Net cash used for operating activities | -43,963 | -31,314 |
| Capital expenditures | 477 | 242 |
| Net cash used for investing activities | -477 | -242 |
| Proceeds from common stock issued under public equity offering-At The Market Offering | 21,227 | 21,236 |
| Proceeds from common stock issued under public equity offering-Public Equity Offering | 79,728 | 0 |
| Proceeds from shares issued under employee stock purchase plan | 50 | 50 |
| Proceeds from exercise of stock options, net | 346 | 7 |
| Proceeds from exercise of warrants, net | 1,430 | - |
| Repayment of debt principal including lease liabilities | 21 | 14 |
| Payments for royalty obligations | 11 | 11 |
| Payments for taxes on share-based compensation | 792 | 722 |
| Net cash provided by financing activities | 101,957 | 20,546 |
| Net increase in cash and cash equivalents | 57,517 | -11,010 |
| Cash and cash equivalents at beginning of period | 71,546 | - |
| Cash and cash equivalents at end of period | 129,063 | - |
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)